ArticleResearch square2023
Methacrylated poly(glycerol sebacate) as a photocurable, biocompatible, and biodegradable polymer with tunable degradation and drug release kinetics.
Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
Poly(glycerol sebacate) (PGS) is a biodegradable, elastomeric polymer that has been explored for applications ranging from tissue engineering to drug delivery and wound repair. Despite its promise, its biomedical utility is limited by its rapid, and largely fixed, degradation rate. Additionally, its preparation requires high temperatures for long periods of time, rendering it incompatible with heat-sensitive molecules, complex device geometries, and high-throughput production. In this study, we synthesized methacrylated PGS (PGS-M), imparting the ability to rapidly photocross-link the polymer. Increasing the degree of methacrylation was found to slow PGS-M degradation; PGS-M (5.5 kDa) disks with 21% methacrylation lost 43% of their mass over 11 weeks in vivo whereas 47% methacrylated disks lost just 14% of their mass over the same period. Increasing the methacrylation also extended the release of encapsulated daunorubicin by up to two orders of magnitude in vitro, releasing drug over months instead of one week. Like PGS, PGS-M exhibited good biocompatibility, eliciting limited inflammation and fibrous encapsulation when implanted subcutaneously. These studies are the first to perform long-term studies demonstrating the ability to tune PGS-M degradation rate, use PGS-M to release drug, demonstrate sustained release of drug from PGS-M, and evaluate PGS-M behavior in vivo. Taken together, these studies show that PGS-M offers several key advantages over PGS for drug delivery and tissue engineering, including rapid curing, facile loading of drugs without exposure to heat, tunable degradation rates, and tunable release kinetics, all while retaining the favorable biocompatibility of PGS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.